Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease
- PMID: 23362306
- DOI: 10.1189/jlb.0112023
Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease
Abstract
Accelerated cardiovascular disease is a frequent complication of CKD. Monocyte-mediated inflammation and adhesion of monocytes to vascular endothelium are key events in atherogenesis. An oral adsorbent, AST-120, retards renal function deterioration by lowering IS, which is known to accumulate in CKD patients. However, the effect of AST-120 on CKD-related monocyte activation is unknown. We aimed to determine whether AST-120 improves monocyte-mediated inflammation through IS reduction. Flow cytometric analysis showed that Mac-1 expression and ROS production were significantly higher in peripheral blood monocytes of subtotal Nx CKD mice than in sham-operated mice. AST-120 treatment significantly decreased Mac-1 expression and ROS production in CKD model mice. Furthermore, administration of IS induced monocyte-mediated inflammation and ROS generation. In vitro studies indicated that IS dose-dependently increased THP-1 monocytic cell adhesion to IL-1β-activated HUVECs under physiological flow conditions. IS also induced monocyte-mediated inflammation and ROS production in THP-1 cells. Phosphorylation of p38 MAPK and membrane translocation of NAD(P)H oxidase subunit p47phox in THP-1 cells were induced by IS. Both SB203580 (p38 MAPK inhibitor) and apocynin [NAD(P)H oxidase inhibitor] reduced THP-1 cell adhesion to HUVECs. Apocynin also inhibited IS-induced ROS production in THP-1 cells. IS induced monocyte-driven inflammation through NAD(P)H oxidase- and p38 MAPK-dependent pathways in monocytes. The main finding of this study was that AST-120 inhibited monocyte activation by reducing IS in vivo. This provides new insights on how AST-120 attenuates the progression of atherosclerosis in CKD.
Keywords: adhesion molecule; atherosclerosis; leukocyte–endothelial interactions; oxidative stress; uremic toxin.
Comment in
-
Editorial: A missing link? Monocyte activation by uremic toxins in cardiorenal syndrome.J Leukoc Biol. 2013 Jun;93(6):821-3. doi: 10.1189/jlb.0113037. J Leukoc Biol. 2013. PMID: 23723377 No abstract available.
Similar articles
-
Oral adsorbent AST-120 ameliorates endothelial dysfunction independent of renal function in rats with subtotal nephrectomy.Hypertens Res. 2009 Mar;32(3):194-200. doi: 10.1038/hr.2008.29. Epub 2009 Jan 16. Hypertens Res. 2009. PMID: 19262482
-
Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.Ther Apher Dial. 2011 Apr;15(2):125-8. doi: 10.1111/j.1744-9987.2010.00883.x. Epub 2011 Jan 25. Ther Apher Dial. 2011. PMID: 21426501
-
Indoxyl Sulfate Contributes to Adipose Tissue Inflammation through the Activation of NADPH Oxidase.Toxins (Basel). 2020 Aug 5;12(8):502. doi: 10.3390/toxins12080502. Toxins (Basel). 2020. PMID: 32764271 Free PMC article.
-
Indoxyl sulfate is a nephro-vascular toxin.J Ren Nutr. 2010 Sep;20(5 Suppl):S2-6. doi: 10.1053/j.jrn.2010.05.002. J Ren Nutr. 2010. PMID: 20797565 Review.
-
The role of carbon adsorbent in the conservative management of chronic kidney disease.Panminerva Med. 2017 Jun;59(2):139-148. doi: 10.23736/S0031-0808.16.03272-9. Epub 2016 Dec 16. Panminerva Med. 2017. PMID: 27990791 Review.
Cited by
-
Protein-Bound Uremic Toxins and Immunity.Methods Mol Biol. 2021;2325:215-227. doi: 10.1007/978-1-0716-1507-2_15. Methods Mol Biol. 2021. PMID: 34053061 Review.
-
Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.BMC Nephrol. 2017 Jan 25;18(1):35. doi: 10.1186/s12882-017-0457-1. BMC Nephrol. 2017. PMID: 28122514 Free PMC article.
-
Cutaneous adaptive immunity and uraemia: a narrative review.Front Immunol. 2024 Sep 27;15:1464338. doi: 10.3389/fimmu.2024.1464338. eCollection 2024. Front Immunol. 2024. PMID: 39399503 Free PMC article. Review.
-
The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders.Toxins (Basel). 2018 Jul 22;10(7):303. doi: 10.3390/toxins10070303. Toxins (Basel). 2018. PMID: 30037144 Free PMC article. Review.
-
TMAO as a potential biomarker and therapeutic _target for chronic kidney disease: A review.Front Pharmacol. 2022 Aug 12;13:929262. doi: 10.3389/fphar.2022.929262. eCollection 2022. Front Pharmacol. 2022. PMID: 36034781 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials